FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Courts Rejecting Loper Arguments in Product Liability: Attorney

Reed Smith attorney James Beck says courts so far have rejected all arguments citing the Supreme Courts Loper Bright decision as a reason to reject pr...

Human Drugs

PDUFA 8 Commitment Letter Analyzed

Akin Gump attorneys highlight major issues in the PDUFA 8 commitment letter that is now open for public comment.

Medical Devices

QMSR Finding Single Risk Thread: Report

MasterControl issues its 2026 life sciences regulatory readiness playbook demonstrating the significant ways in which the FDA Quality System Managemen...

latest-news-card-1
Marketing

FDA Promotion Crackdown Enters New Phase: Attorneys

Attorneys from Arnall Golden Gregory examine and offer advice on FDAs intensified scrutiny of drug advertising, advising companies to prepare for clos...

latest-news-card-1
Human Drugs

Senate Report Raises Questions About Oversight of Mifepristone Providers

A new report from Senate HELP chair Bill Cassidy (R-LA) targets FDA for allowing the abortion drug mifepristones Risk Evaluation and Mitigation Strate...

latest-news-card-1
Human Drugs

Osfamide Shortage Seen

An oncology physician association says its members are reporting a shortage of the chemotherapy agent ifosfamide for which no direct substitute is ava...

latest-news-card-1
Medical Devices

FDA Issues Alert on Abiomed Impella Controllers

CDRH issues an early alert to notify the public about an Abiomed action recommending that all Automated Impella Controllers be removed from where they...

latest-news-card-1
Human Drugs

Petition Seeks Carbetocin OK for Postpartum Hemorrhage

Two physicians affiliated with Stanford Universitys medical school urge FDA to approve carbetocin for preventing postpartum hemorrhage.

latest-news-card-1
FDA General

HHS to Appoint 2 New FDA Deputy Commissioners: CNBC

CNBC reports that HHS plans to appoint two new FDA deputy commissioners in hopes of exerting more influence over the agency.

latest-news-card-1
Medical Devices

Boston Scientific ENROUTE System Recall is Class 1

FDA says the Boston Scientific recall of its ENROUTE Transcarotid Neuroprotection System is Class 1.